PBPH vs PPH

PBPHBPortfolio Building Block World Pharma and Biotech Index ETF

PPHAVanEck Pharmaceutical ETF

In short

PBPH Most biotech funds stop at the US border. PBPH buys the developed world's drug complex, pharma and biotech together, through a plain index fund charging 0.13%.

PPH About two dozen US-listed drugmakers in one ticker, tracking the MVIS US Listed Pharmaceutical 25 Index since 2011. VanEck charges well under the pharma-fund median to run it.

Stated mandate

PBPH The Fund seeks to track, before fees and expenses, the performance of the BITA Global Pharma and Biotech Select Index.

PPH The fund seeks to track, before fees and expenses, the performance of the MVIS US Listed Pharmaceutical 25 Index, which covers companies involved in pharmaceutical research and development, production, marketing, and sales.

Why people hold it

• PBPH 0.13% a year, in a global thematic aisle where the typical fund charges several times that. Fee drag is about as small as this shelf gets.
• Pharma and biotech under one ticker, global rather than US-only, so overseas drugmakers sit alongside the American names.portfoliobuildingblocketfs.com
• Straight index replication inside an ordinary 1940 Act fund. Published rules do the picking, not a manager's hunch.
• Cheap build plus workable trading puts it among the stronger implementations in its global thematic peer group.

• PPH Costs 0.36% a year against a 0.57% median for pharma ETFs, undercutting peers like PJP and FTXH.
• Focused by design: the index tracks US-listed pharmaceutical companies (research, production, marketing, sales) rather than the whole health care aisle.vaneck.com
• Trading since 2011, one of the veterans of the pharma shelf, and it sits in the top quartile of its peer group on our review.
• Pays out quarterly, and it is a moderately traded fund, so getting in and out is usually straightforward.

Worth knowing

• PBPH One industry, one storyline. Drug pricing rules, patent cliffs and trial readouts swing this basket in ways the broad market does not feel.
• Launched in late 2025, so there is no long live record showing how closely it hugs the index across a full cycle.
• Cash comes back once or twice a year, not monthly. This is an exposure holding, not an income schedule.

• PPH Around 26 holdings. One company's trial result or patent cliff carries real weight in a basket this tight.
• Single-sector health care exposure: drug pricing politics and regulation land on the whole basket at once, with nothing else to cushion it.
• The fee edge over the category is real, but XPH sits at 0.35%, so cost alone is not what separates these two.

Full PBPH profile⁠

Full PPH profile⁠